Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)
94.03
-3.30 (-3.39%)
Mar 9, 2026, 3:00 PM CST
SHA:688578 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 586.99 | 1,862 | 470.49 | 615.36 |
Short-Term Investments | - | 280 | 230 | - | 20 |
Trading Asset Securities | - | 2,759 | 419.6 | 1,567 | 1,625 |
Cash & Short-Term Investments | 3,279 | 3,626 | 2,512 | 2,037 | 2,260 |
Cash Growth | -9.59% | 44.37% | 23.29% | -9.86% | -12.78% |
Accounts Receivable | - | 389 | 260.17 | 150.85 | 14.83 |
Other Receivables | - | 29.26 | 29.07 | 6.82 | 3.58 |
Receivables | - | 418.26 | 289.24 | 157.68 | 18.42 |
Inventory | - | 30.56 | 62.95 | 32.07 | 20.8 |
Prepaid Expenses | - | 2.15 | 3.18 | 2.5 | - |
Other Current Assets | - | 103.21 | 40.79 | 56.69 | 75.42 |
Total Current Assets | - | 4,180 | 2,908 | 2,286 | 2,375 |
Property, Plant & Equipment | - | 516.37 | 526.64 | 539.94 | 404.03 |
Long-Term Investments | - | 244.4 | 145.26 | 52.73 | 38.37 |
Other Intangible Assets | - | 65.38 | 66.49 | 68.45 | 67.29 |
Long-Term Deferred Tax Assets | - | 0 | - | 11.5 | - |
Long-Term Deferred Charges | - | 168.12 | 0.71 | 0.57 | 2.11 |
Other Long-Term Assets | - | 741.45 | 729.5 | 482.76 | 243.79 |
Total Assets | - | 5,916 | 4,376 | 3,442 | 3,130 |
Accounts Payable | - | 27.39 | 13.25 | 5.15 | 1.75 |
Accrued Expenses | - | 482.4 | 314.33 | 152.68 | 96.96 |
Current Portion of Leases | - | 0.99 | 1.43 | 1.66 | 4.72 |
Current Income Taxes Payable | - | 67.45 | 5.4 | 6.98 | - |
Current Unearned Revenue | - | - | - | 0.1 | 0.18 |
Other Current Liabilities | - | 22.37 | 55.62 | 88.04 | 52.51 |
Total Current Liabilities | - | 600.6 | 390.03 | 254.62 | 156.12 |
Long-Term Leases | - | 0.3 | 0.39 | 0.3 | 0.68 |
Long-Term Deferred Tax Liabilities | - | 28.77 | 0.14 | - | - |
Other Long-Term Liabilities | - | 3.65 | 3.65 | 0.2 | 0.2 |
Total Liabilities | - | 633.32 | 394.22 | 255.12 | 156.99 |
Common Stock | - | 450 | 450 | 450 | 450 |
Additional Paid-In Capital | - | 3,254 | 3,175 | 3,100 | 3,031 |
Retained Earnings | - | 1,401 | 264.02 | -380.16 | -510.68 |
Comprehensive Income & Other | - | 177.89 | 93.63 | 17.61 | 3.25 |
Shareholders' Equity | 6,499 | 5,283 | 3,982 | 3,187 | 2,973 |
Total Liabilities & Equity | - | 5,916 | 4,376 | 3,442 | 3,130 |
Total Debt | 3.75 | 1.3 | 1.82 | 1.96 | 5.39 |
Net Cash (Debt) | 3,275 | 3,625 | 2,510 | 2,035 | 2,255 |
Net Cash Growth | -9.66% | 44.42% | 23.32% | -9.73% | -12.99% |
Net Cash Per Share | 7.28 | 8.06 | 5.57 | 4.52 | 4.94 |
Filing Date Shares Outstanding | 450 | 450 | 450 | 450 | 450 |
Total Common Shares Outstanding | 450 | 450 | 450 | 450 | 450 |
Working Capital | - | 3,580 | 2,518 | 2,032 | 2,219 |
Book Value Per Share | 14.44 | 11.74 | 8.85 | 7.08 | 6.61 |
Tangible Book Value | 6,321 | 5,217 | 3,916 | 3,119 | 2,906 |
Tangible Book Value Per Share | 14.05 | 11.59 | 8.70 | 6.93 | 6.46 |
Buildings | - | 508.81 | 494.91 | 470.35 | 116.73 |
Machinery | - | 156.45 | 132.04 | 140.27 | 88.34 |
Construction In Progress | - | 5.19 | 18.58 | 13.8 | 266.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.